Zurich’s flagship adult-use cannabis trial, Züri Can, could now run until 2028 after city officials applied this week to extend the project by two years, citing strong early results in reducing illicit sales and promoting safer consumption. The move comes as the Swiss Federal Government continues [...]
The Lebanese government has established a regulatory body to oversee legal cannabis production for pharmaceutical purposes, in the hope of transforming the country's struggling economy whilst ending decades of illegal cultivation. This story first appeared on leafie, view here Author: Liam O'Dowd
Healthcare professionals attending the Cannabis Health Symposium next month will be able to earn CPD points to support their professional development. The Cannabis Health Symposium is a Continuing Professional Development (CPD)-accredited event, meaning attendees can earn professional development credits as a result of their participation. The [...]
MariMed, one of the nation’s leading multi-state cannabis operators, began in the medical cannabis market and expanded into adult-use as states legalized. Through this growth, the company has remained true to its “medical-first” approach, ensuring that product quality, safety, and consistency remain at the core of [...]
A large study of over 66,000 patients diagnosed with alcohol use disorder found that heavy cannabis users are up to 40% less likely to develop severe liver complications. This story first appeared on leafie, view here Author: Kevin Dinneen
For decades, cannabis has lived in a research dead zone. Federal prohibition has blocked meaningful grants, limited clinical trials, and left millions of people with cancer relying on anecdotal evidence for treatment rather than data. As founders of E.R.I.C. Cancer Playbook, we refused to accept that. [...]
Researchers have created a synthetic compound from caraway seeds that shows greater effectiveness than current childhood epilepsy medications, offering hope for safer treatments without cannabis-related regulatory barriers. This story first appeared on leafie, view here Author: Kevin Dinneen
Jason Ambrosino, a disabled Army veteran and founder of Veterans Holdings, entered the New York market in 2019 under the state’s hemp program with the goal of cultivating and manufacturing cannabis. But despite holding a 5,000-square-foot indoor cultivation license, he decided not to build out his [...]
More than 2,300 people have been able to purchase cannabis legally through the city's pilot programme, with officials citing it's success in undermining the black market. This story first appeared on leafie, view here Author: Liam O'Dowd
New research reveals that people who use both cannabis and tobacco have significantly different brain chemistry compared to cannabis-only users, potentially explaining higher rates of anxiety, depression, and addiction in co-users. This story first appeared on leafie, view here Author: Kevin Dinneen
In her new bi-weekly series for Cannabis Health, Dr Sue Clenton, Consultant Oncologist and Medical Director at Releaf Cannabis Clinic, shares her insight from the front line of an emerging field of medicine, taking readers inside the clinic and offering a doctor’s perspective on what it [...]
Almost seven years since medical cannabis was legalised in the UK on 1st November 2018, less than 1% of the UK’s approximate 100,000 doctors on the General Medical Council (GMC) Specialist Register have the training required to prescribe medical cannabis. While the UK’s medical cannabis market [...]
A growing number of patients are now prescribed medical cannabis for common mental health issues and neurodiverse conditions, such as autism and ADHD. Ahead of Cannabis Health Symposium next month, we examine the research and real-world evidence behind the use of cannabis-based medicines in psychiatry. Many [...]
A new health-tech company, EM2P2, has launched CannaLnx, a HIPAA-compliant platform it claims will make medical cannabis reimbursable under traditional health insurance plans for the first time in the U.S. The system, announced in partnership with the American Council of Cannabis Medicine (ACCM), is described as [...]
Curaleaf Laboratories has been confirmed as headline sponsor of the inaugural Cannabis Health Symposium, taking place on 25 November 2025 at Conway Hall, London. The event, delivered in partnership with the Medical Cannabis Clinicians Society (MCCS), will focus on strengthening clinical understanding and confidence in prescribing [...]
The Advisory Council on the Misuse of Drugs (ACMD) has closed its latest call for evidence into the impact of medical cannabis legalisation, in what will mark the most comprehensive review of the UK’s cannabis-based products for medicinal use (CBPM) framework since it was introduced in [...]
In cannabis, it sometimes feels like every financial conversation ends the same way: “If not for 280E, we’d be thriving.” That line gets repeated in boardrooms and investor decks across the country, and for good reason. Section 280E has choked margins, slowed growth, and kept great [...]
A comprehensive survey of over 113,000 teenagers across Europe has revealed declining alcohol and drug use but rising concerns over e-cigarettes, social media addiction and online gambling, particularly among girls. This story first appeared on leafie, view here Author: Liam O'Dowd
Most cannabis dispensaries are small businesses. That often means they operate on tight margins and require employees to take on roles outside their typical job descriptions. It’s common for owners or general managers to handle HR and payroll functions themselves. What begins as an understandable cost-saving measure, however, [...]
Research involving nearly 140,000 participants found that frequent cannabis users had significantly reduced odds of developing common sinus conditions when compared to non-users. This story first appeared on leafie, view here Author: Kevin Dinneen
Multiple scientific studies and lab results have provided compelling evidence that terpenes and volatile metabolites in cannabis rapidly degrade when exposed to light, oxygen, heat, and time, and therefore, reduce the entourage effect that depends on a specific balance of cannabinoids and terpenes. Because of this, [...]
We, The Patients have announced they will host a free medical cannabis education event in London in November to bridge the understanding between patients and healthcare professionals. This story first appeared on leafie, view here Author: Liam O'Dowd
How one oncologist is helping redefine patient care and the future of integrated healthcare. Medical cannabis is starting to have a very different kind of conversation in the UK. From mainstream voices like Rory Cellan-Jones exploring patient experiences on his Movers & Shakers podcast, to growing [...]
German pharmaceutical company Vertanical believes it is on course to deliver the first ‘whole-plant’, cannabis medicine with international approval. After seven years of endeavour, and an investment of over $250m, its VER-01 chronic pain-relief drug has passed a Phase 3 trial in its home market. As [...]
As the prevalence of dementia and other neurodegenerative conditions continues to rise globally, there is growing interest in the role of cannabis-based medicines in symptom management. A small number of studies, combined with real-world clinical experience is beginning to provide important insights into the potential of [...]
Target’s decision to start selling hemp-derived THC beverages marks a major milestone for the cannabis industry and a reality check for brands hoping to follow. Selling into mass retail is not just about scaling production or packaging appeal. It requires proving that your product meets the [...]
The private medical cannabis clinic Alternaleaf says it is responding to the “medical misogyny” crisis that has left 630,000 women waiting for NHS gynaecology care, with endometriosis taking an average eight years to diagnose. This story first appeared on leafie, view here Author: Liam O'Dowd
Medical cannabis patients will host a major educational event in the UK next month, aiming to bridge the gap between patients and healthcare professionals through evidence, empathy and lived experience. The international patient-led organisation We, The Patients, will bring its educational series to London next month [...]
Research involving over 130,000 people reveals genetic variants associated with brain signalling and impulsivity may also influence cannabis use patterns. This story first appeared on leafie, view here Author: Kevin Dinneen
In cannabis, it sometimes feels like every financial conversation ends the same way: “If not for 280E, we’d be thriving.” That line gets repeated in boardrooms and investor decks across the country, and for good reason. Section 280E has choked margins, slowed growth, and kept great [...]
Global cannabis trade is well underway as legalized countries move forward to establish a supply chain infrastructure in a newly formed and rapidly evolving industry. At the forefront of transportation logistics is Cannabilog, an Israeli company led by pharmaceutical industry veteran Yoram Eshel. In an interview, [...]
The soil cannabis is grown in directly affects the levels of cannabinoids such as CBD, CBG and THC, a first-of-its-kind, federally funded study has found. This story first appeared on leafie, view here Author: Kevin Dinneen
Experts say real-world evidence could offer crucial insights into how these medicines work in practice, and help widen access for patients. For the last 50 years, randomised controlled trials (RCTs) have been considered the ‘gold standard’ research methodology for measuring the safety and efficacy of new [...]
New research suggests the popular opioid painkiller offers minimal relief for chronic pain whilst significantly increasing the risk of heart problems and other serious side effects, highlighting the need for alternative, safer treatments, such as cannabis. This story first appeared on leafie, view here Author: Liam [...]
In a historic move, Spain’s Council of Ministers has approved a long-awaited Royal Decree regulating the medicinal use of cannabis preparations in hospital settings. Following years of advocacy on behalf of patients and campaigners, the decision marks a decisive step toward the integration of medical cannabis [...]
As our bodies age, the mechanisms that keep our systems humming, such as immune regulation, metabolism, and neural repair, gradually erode. That loss of homeostasis is the culprit behind many age-related disorders, from cognitive decline to metabolic dysfunction. Scientists are beginning to explore whether cannabis or [...]
A Royal Decree has authorised the limited use of medical cannabis in hospitals, allowing specialists to issue prescriptions for oils when treating conditions where conventional treatments have proved ineffective. This story first appeared on leafie, view here Author: Liam O'Dowd
Germany’s booming cannabis market, which Prohibition Partners now estimates to be worth around €670m, is entering uncertain and potentially treacherous territory. As the landmark CanG Act approaches its second year, it has become a highly charged and increasingly divisive issue politically, culturally, and medically. With the [...]
The study revealed that cannabis use initiated in later life may offer therapeutic benefits, while lifetime use beginning early could harm cognitive function in older adults. This story first appeared on leafie, view here Author: Kevin Dinneen
Q&A with Brendan McGee, Founder, Silver Therapeutics Tell us about your product(s). What do you make or sell, and what should people know about it? At Silver Therapeutics, we’re driven to curate experiences that meet people where they are. From flower to prerolls to vapes, we [...]
Alibi Cannabis website. Q&A Tell us about your product(s). What do you make or sell, and what should people know about it? Our roots are in cultivation, so everything starts with high-quality flowers. In Oregon, our flower has won multiple awards, and we bring that focus [...]
Website: rosareta.com Tell us about your product(s). What do you make or sell, and what should people know about it? Rosa Reta crafts solventless cannabis Live Rosin vapes (All-In-One), Bubble Hash Infused prerolls, and Rosin infused gummies. We focus on clean processing, full-spectrum flavor, and consistent quality [...]
The cannabis industry’s fragmented foundation is creating a host of problems tied to the lack of federal legalization. Many experts believe that without a national medical cannabis framework, the future of cannabis as a medicine in America could leave patients unprotected, research underfunded, and the industry [...]
At PatientsCann UK, we represent the voices of patients who rely on safe, effective, and regulated access to medical cannabis. Since its legalisation in 2018, many people have continued to face unnecessary barriers to treatment, from stigma and misinformation to the limited availability of NHS prescriptions. For thousands of patients, private prescriptions remain the only viable route to accessing the medicine they need. That’s why the Department of Health and Social Care’s “Private (non-NHS) Prescribing: Call for Evidence” is such an important opportunity. This review could influence how private prescribing works in the UK, including how cannabis-based medicines are accessed, regulated, and supported by clinicians. Why This Matters The call for evidence invites responses from across the healthcare system, including clinicians, prescribers, pharmacists, healthcare organisations, and patient groups. While the questions are primarily aimed at professionals, it is crucial that patients and carers also share their experiences. By contributing evidence and lived experience, we can help policymakers understand: How private prescribing supports patients who are unable to access NHS treatment. The challenges of affordability, continuity of care, and stigma in private medical cannabis access. The need for greater clinical education and confidence around prescribing cannabis-based medicines. The importance of protecting safe, regulated, and equitable access for all patients. Our Position PatientsCann UK believes that this review must:Protect the right of patients to access regulated medical cannabis safely and affordably.Promote fairness and consistency between NHS and private prescribing pathways.Address stigma and empower clinicians to prescribe based on evidence, not fear.Encourage more research, education, and evidence-based practice across the medical field. This consultation provides a rare chance to shape how the UK approaches private prescribing, and to ensure medical cannabis patients are not overlooked. How to Take Part Your experience is evidence — share it.The Private (non-NHS) Prescribing: Call for Evidence is now open to submissions from individuals and organisations with knowledge or experience of private prescribing. Visit: Private (non-NHS) Prescribing: Call for Evidence – GOV.UKDeadline: 11:59 pm, 4 November 2025 You do not need to answer every question, but you must select Submit at the end for your response to count. How Patients Can Encourage Healthcare Professionals You can play an important role in raising awareness of this consultation within your own care networks. Here are a few ways to help: Start the conversation. Mention the review to your prescribing clinician, pharmacist, or nurse and let them know the deadline. Many professionals may not yet be aware of it. Share the link. Send your clinic, GP practice, or specialist the official GOV.UK consultation page and encourage them to share it with colleagues. Speak to both sides. Whether your care is through a private medical cannabis clinic or the NHS, professionals across both systems can contribute valuable insight on access, patient safety, and clinical challenges. Explain why it matters. Let them know that evidence from healthcare professionals — especially those working with medical cannabis — can directly shape how government policy supports safer and fairer access for patients. Spread awareness. Share our post and tag your clinic, pharmacy, or medical organisation on social media to encourage wider participation. Your voice can help ensure that both patients and healthcare professionals are represented in this important review. Important Note This consultation is separate from the ACMD call for evidence on cannabis-based medicinal products, which focuses on clinical data and scheduling. Both reviews are crucial, and we encourage responses to each. Together, we can ensure that clinicians, patients, and organisations play a leading role in shaping an equitable and evidence-based future for medical cannabis access in the UK. 💚
The post Help Shape The Future of Medical Cannabis first appeared on PatientsCann UK.
A comprehensive survey of 1,450 chronic pain patients found that 86% reported moderate to significant pain improvement after using medical cannabis, with over a third able to eliminate other prescription medications entirely. This story first appeared on leafie, view here Author: Liam O'Dowd
The cannabis industry is a fertile ground for aspiring entrepreneurs, holding the promise of a modern-day gold rush. Yet beneath the surface of opportunity lies a minefield of obstacles. Success requires navigating a steep learning curve, managing high operational costs, and mastering a complex supply chain [...]
Dr Sue Clenton, Medical Director of Releaf cannabis clinic explains what it takes to go from a few hundred to thousands of patients, without compromising on the quality of care. When people talk about growth in healthcare, the conversation often centres on numbers – the number [...]
New guidelines around THC levels, dosages, and eligibility, aim to bring more clarity and consistency to the practice of prescribing cannabis-based medicines in the UK. Almost seven years since medical cannabis was legalised in the UK, around 180 specialist consultants are now actively prescribing. But almost [...]
The Advisory Council on the Misuse of Drugs (ACMD) is reviewing cannabis-based products for medicinal use (CBPMs).
The post PatientsCann UK Statement on the ACMD Review of Medical Cannabis first appeared on PatientsCann UK.
Research commissioned by the German government has found that teenage cannabis consumption has fallen since Germany's Cannabis Act (CanG) became law in April 2024. This story first appeared on leafie, view here Author: Liam O'Dowd
Copyright © 2020 – 2026 | The Cannabis Pages | All Rights Reserved | Important Notice | The Cannabis Pages “TCP” is an information resource for medical cannabis patients and prescribers. Nothing on the site should be construed as a promotion or inducement. TCP does not promote any product or represent that the products mentioned on TCP’s website are treatment for any kind of medical condition. TCP cannot guarantee that information provided is error-free or complete and is not responsible for the quality of the information provided by users. Cannabis is an unlicensed medication which can only be administered under the supervision of a licensed physician.
